Immutep (IMMP) has released an update.
Immutep announces promising initial results from its Phase II EFTISARC-NEO trial, showing that its novel combination of eftilagimod alpha (efti) with radiotherapy and KEYTRUDA is well tolerated in soft tissue sarcoma patients. Four out of six patients exhibited near-complete responses, a significant improvement over typical outcomes with standard treatments. As the study continues, further data is expected to be presented in the second half of 2024.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
